Literature DB >> 8620511

Human colorectal carcinomas express high levels of high mobility group HMGI(Y) proteins.

M Fedele1, A Bandiera, G Chiappetta, S Battista, G Viglietto, G Manfioletti, A Casamassimi, M Santoro, V Giancotti, A Fusco.   

Abstract

A correlation has previously been demonstrated between the presence of the three HMGI proteins (HMGI, HMGY, and HMGI-C) and the expression of a highly malignant phenotype in epithelial and fibroblastic rat thyroid cells; this being subsequently extended to experimental thyroid, lung, prostate, mammary, and skin carcinomas. Recently, we have demonstrated that expression of HMGI and HMGY proteins, coded for by the HMGI(Y) gene, is associated with the malignant phenotype of human thyroid neoplasias. Here, we show that HMGI(Y) gene expression is present both at the RNA and protein level in human colorectal carcinoma cell lines and tissues examined in this study. Conversely, no HMGI(Y) proteins were detected in normal intestinal mucosa. Therefore, these results suggest an involvement of HMGI and HMGY proteins overexpression in colorectal tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8620511

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

Review 1.  The high mobility group A1 molecular switch: turning on cancer - can we turn it off?

Authors:  Tait H Huso; Linda M S Resar
Journal:  Expert Opin Ther Targets       Date:  2014-03-31       Impact factor: 6.902

2.  Neoplastic transformation of rat thyroid cells requires the junB and fra-1 gene induction which is dependent on the HMGI-C gene product.

Authors:  D Vallone; S Battista; G M Pierantoni; M Fedele; L Casalino; M Santoro; G Viglietto; A Fusco; P Verde
Journal:  EMBO J       Date:  1997-09-01       Impact factor: 11.598

Review 3.  High mobility group proteins and their post-translational modifications.

Authors:  Qingchun Zhang; Yinsheng Wang
Journal:  Biochim Biophys Acta       Date:  2008-05-10

Review 4.  High mobility group A: a novel biomarker and therapeutic target in pancreatic adenocarcinoma.

Authors:  S S Liau; E Whang
Journal:  Surgeon       Date:  2009-10       Impact factor: 2.392

5.  NF-kappaB mediated transcriptional activation is enhanced by the architectural factor HMGI-C.

Authors:  F Mantovani; S Covaceuszach; A Rustighi; R Sgarra; C Heath; G H Goodwin; G Manfioletti
Journal:  Nucleic Acids Res       Date:  1998-03-15       Impact factor: 16.971

6.  Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma.

Authors:  Gustavo Baldassarre; Sabrina Battista; Barbara Belletti; Sanjay Thakur; Francesca Pentimalli; Francesco Trapasso; Monica Fedele; Giovanna Pierantoni; Carlo M Croce; Alfredo Fusco
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

7.  Gene expressions of HMGI-C and HMGI(Y) are associated with stage and metastasis in colorectal cancer.

Authors:  Meng-Lin Huang; Chou-Chan Chen; Li-Ching Chang
Journal:  Int J Colorectal Dis       Date:  2009-07-17       Impact factor: 2.571

8.  High-mobility group A1 proteins are overexpressed in human leukaemias.

Authors:  Giovanna Maria Pierantoni; Valter Agosti; Monica Fedele; Heather Bond; Irene Caliendo; Gennaro Chiappetta; Francesco Lo Coco; Fabrizio Pane; Maria Caterina Turco; Giovanni Morrone; Salvatore Venuta; Alfredo Fusco
Journal:  Biochem J       Date:  2003-05-15       Impact factor: 3.857

9.  Human papilloma virus-dependent HMGA1 expression is a relevant step in cervical carcinogenesis.

Authors:  Massimiliano Mellone; Christian Rinaldi; Isabella Massimi; Marialaura Petroni; Veronica Veschi; Claudio Talora; Silvia Truffa; Helena Stabile; Luigi Frati; Isabella Screpanti; Alberto Gulino; Giuseppe Giannini
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

10.  HMGI(Y) gene expression as a potential marker of thyroid follicular carcinoma.

Authors:  W Czyz; E Balcerczak; M Jakubiak; Z Pasieka; K Kuzdak; M Mirowski
Journal:  Langenbecks Arch Surg       Date:  2004-04-24       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.